GENMAB A/S/S (OTCMKTS:GMXAY) Share Price Passes Above Fifty Day Moving Average – Should You Sell?

GENMAB A/S/S (OTCMKTS:GMXAY)’s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $28.32 and traded as high as $31.98. GENMAB A/S/S shares last traded at $31.94, with a volume of 3,427,175 shares trading hands.

GENMAB A/S/S Stock Performance

The stock’s fifty day simple moving average is $28.46 and its 200-day simple moving average is $27.95.

Hedge Funds Weigh In On GENMAB A/S/S

A hedge fund recently bought a new position in GENMAB A/S/S stock. Madison Asset Management LLC bought a new stake in GENMAB A/S/S (OTCMKTS:GMXAY) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 70,781 shares of the company’s stock, valued at approximately $1,944,000.

GENMAB A/S/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.

Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.